BTIG initiated coverage on United Therapeutics Corporation (NASDAQ: UTHR) Monday with a Neutral rating. Analyst Hartaj Singh believed a “late-2017 patent cliff for 3 out of 4 of its top products that could reduce 2018 adjusted EPS to 2013 levels (~$6-7/share) is offset by the blue sky. Read More.